1	Long-term efficacy of satralizumab in AQP4-IgG-
2	seropositive neuromyelitis optica spectrum disorder
3	(NMOSD) from SAkuraSky and SAkuraStar
4	
5	Supplementary materials
6	
7	Authors
, 8	Ingo Kleiter, Anthony Traboulsee, Jacqueline Palace, Takashi Yamamura, Kazuo Fujihara,
9	Albert Saiz, Adil Javed, David Mayes, H-Christian von Büdingen, Gaelle Klingelschmitt,
10	Daniela Stokmaier, Jeffrey L Bennett
11	
11	
12	Detailed inclusion and exclusion criteria for the SAkura studies
13	SAkuraSky: inclusion criteria
14	1. Patients diagnosed as having either:
15	 NMO as defined by Wingerchuk et al. 2006¹, which required the following:
16	i. Optic neuritis
17	ii. Acute myelitis
18	iii. At least two of three supportive criteria:
19	1. Contiguous spinal cord lesion identified on an MRI scan
20	extending over 3 vertebral segments
21	2. Brain MRI not meeting diagnostic criteria for MS
22	3. NMO-immunoglobulin G (IgG) (anti-AQP4 antibody)
23	seropositive status
24	 NMOSD as defined by either of the following criteria with anti-AQP4
25	antibodies seropositive status at screening (Wingerchuk 2007 ²):
26	i. Idiopathic single or recurrent events of longitudinally extensive myelitis
27	(≥3 vertebral segment spinal cord MRI lesion)
28	ii. Optic neuritis: recurrent or simultaneous bilateral
29	2. Clinical evidence of at least 2 documented relapses (including first attack) in the last
30	2 years prior to screening, at least one of which had occurred in the 12 months prior
31	to screening.
32	3. Expanded Disability Status Scale (EDSS) score from 0 to 6.5 inclusive at screening.

4. Age 12 to 74 years, inclusive at the time of informed consent.

- 5. One of the following baseline treatments at stable dose as a monotherapy for 8
- 35 weeks prior to baseline:
 - i. Azathioprine
 - ii. Mycophenolate mofetil
- 38 iii. Oral corticosteroids
- 39 o Adolescents had the option of oral corticosteroids in addition to azathioprine
 40 or mycophenolate mofetil
- 41 6. Ability and willingness to provide written informed consent and to comply with the42 requirements of the protocol.

43 SAkuraSky: exclusion criteria

44 **Prior therapies**

36

37

- Any previous treatment with interleukin-6 (IL-6) inhibitory therapy (e.g. tocilizumab),
 alemtuzumab, total body irradiation or bone marrow transplantation at any time.
- 47 2. Any previous treatment with anti-CD20, eculizumab, belimumab, interferon,
 48 natalizumab, glatiramer acetate, fingolimod, teriflunomide or dimethyl fumarate within
 49 6 months prior to baseline.
- Any previous treatment with anti-CD4, cladribine or mitoxantrone within 2 years prior
 to baseline
- 52 4. Treatment with any investigational agent within 3 months prior to baseline.

53 General safety

- 54 5. Pregnancy or lactation.
- For patients of reproductive potential, a positive result from a serum pregnancy test
 at screening, or not willing to use reliable means of contraception (physical barrier
 [patient or partner] in conjunction with a spermicidal product, contraceptive pill, patch,
 injectables, intrauterine device or intrauterine system) during the treatment period
- 59 and for at least 3 months after the last dose of study drug.
- 60 7. Any surgical procedure (except for minor surgeries) within 4 weeks prior to baseline.
- 8. Evidence of other demyelinating disease or progressive multifocalleukoencephalopathy (PML).
- 63 9. Evidence of serious uncontrolled concomitant diseases that may preclude patient
 64 participation, such as other nervous system disease, cardiovascular disease,
- 65 hematologic/hematopoiesis disease, respiratory disease, muscular disease,
- endocrine disease, renal/urologic disease, digestive system disease, congenital or
 acquired severe immunodeficiency.

68	10. Known active infection (excluding fungal infections of nail beds or caries dentium)
69	within 4 weeks prior to baseline.
70	11. Evidence of chronic active hepatitis B or C.
71	12. History of drug or alcohol abuse within 1 year prior to baseline.
72	13. History of diverticulitis that, in the Investigator's opinion, may lead to increased risk of
73	complications such as lower gastrointestinal perforation.
74	14. Evidence of active TB (excluding patients receiving chemoprophylaxis for latent TB
75	infection).
76	15. Evidence of active interstitial lung disease.
77	16. Receipt of any live or live attenuated vaccine within 6 weeks prior to baseline.
78	17. History of malignancy within the last 5 years, including solid tumors, hematologic
79	malignancies and in situ carcinoma (except basal cell and squamous cell carcinomas
80	of the skin, or in situ carcinoma of the cervix uteri that have been completely excised
81	and cured).
82	18. History of severe allergic reaction to a biologic agent (e.g. shock, anaphylactic
83	reactions).
84	19. Active suicidal ideation within 6 months prior to screening, or history of suicide
85	attempt within 3 years prior to screening.
86	Laboratory exclusion criteria (at screening)
86 87	Laboratory exclusion criteria (at screening) 20. Following laboratory abnormalities at screening*:
87	20. Following laboratory abnormalities at screening*:
87 88	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) <3.0 ≥10³/μL
87 88 89	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) <3.0 ≥10³/μL ii. Absolute neutrophil count (ANC) <2.0 ≥10³/μL
87 88 89 90	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) <3.0 ≥10 ³ /μL ii. Absolute neutrophil count (ANC) <2.0 ≥10 ³ /μL iii. Absolute lymphocyte count <0.5 ≥10 ³ /μL
87 88 89 90 91	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) <3.0 ≥10 ³ /μL ii. Absolute neutrophil count (ANC) <2.0 ≥10 ³ /μL iii. Absolute lymphocyte count <0.5 ≥10 ³ /μL iv. Platelet count <10 ≥10 ⁴ /μL
87 88 89 90 91 92	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) $<3.0 \ge 10^3/\mu$ L ii. Absolute neutrophil count (ANC) $<2.0 \ge 10^3/\mu$ L iii. Absolute lymphocyte count $<0.5 \ge 10^3/\mu$ L iv. Platelet count $<10 \ge 10^4/\mu$ L v. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT)
87 88 90 91 92 93 94	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) $\langle 3.0 \ge 10^3/\mu L$ ii. Absolute neutrophil count (ANC) $\langle 2.0 \ge 10^3/\mu L$ iii. Absolute lymphocyte count $\langle 0.5 \ge 10^3/\mu L$ iv. Platelet count $\langle 10 \ge 10^4/\mu L$ v. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria
87 88 90 91 92 93 94 95	20. Following laboratory abnormalities at screening*: i. White blood cells (WBC) $\langle 3.0 \ge 10^3/\mu L$ ii. Absolute neutrophil count (ANC) $\langle 2.0 \ge 10^3/\mu L$ iii. Absolute lymphocyte count $\langle 0.5 \ge 10^3/\mu L$ iv. Platelet count $\langle 10 \ge 10^4/\mu L$ v. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria 1. Patients diagnosed as having either:
87 88 90 91 92 93 94 95 96	 20. Following laboratory abnormalities at screening*: White blood cells (WBC) <3.0 ≥10³/µL Absolute neutrophil count (ANC) <2.0 ≥10³/µL Absolute lymphocyte count <0.5 ≥10³/µL Platelet count <10 ≥10⁴/µL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria Patients diagnosed as having either: NMO as defined by Wingerchuk et al. 2006¹, which required the following:
87 88 90 91 92 93 94 95 96 97	 20. Following laboratory abnormalities at screening*: White blood cells (WBC) <3.0 ≥10³/µL Absolute neutrophil count (ANC) <2.0 ≥10³/µL Absolute lymphocyte count <0.5 ≥10³/µL Platelet count <10 ≥10⁴/µL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria Patients diagnosed as having either: NMO as defined by Wingerchuk et al. 2006¹, which required the following: Optic neuritis
87 88 90 91 92 93 94 95 96 97 98	 20. Following laboratory abnormalities at screening*: White blood cells (WBC) <3.0 ≥10³/µL Absolute neutrophil count (ANC) <2.0 ≥10³/µL Absolute lymphocyte count <0.5 ≥10³/µL Platelet count <10 ≥10⁴/µL Platelet count <10 ≥10⁴/µL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria Patients diagnosed as having either: Optic neuritis Acute myelitis
87 88 90 91 92 93 94 95 96 97 98 99	 20. Following laboratory abnormalities at screening*: White blood cells (WBC) <3.0 ≥10³/µL Absolute neutrophil count (ANC) <2.0 ≥10³/µL Absolute lymphocyte count <0.5 ≥10³/µL Platelet count <10 ≥10⁴/µL Platelet count <10 ≥10⁴/µL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria Patients diagnosed as having either: Optic neuritis Acute myelitis Acute myelitis At least two of three supportive criteria:
87 88 90 91 92 93 94 95 96 97 98 99 100	 20. Following laboratory abnormalities at screening*: White blood cells (WBC) <3.0 ≥10³/μL Absolute neutrophil count (ANC) <2.0 ≥10³/μL Absolute lymphocyte count <0.5 ≥10³/μL Platelet count <10 ≥10⁴/μL Platelet count <10 ≥10⁴/μL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria Patients diagnosed as having either: Optic neuritis Acute myelitis Acute myelitis At least two of three supportive criteria: Contiguous spinal cord lesion identified on an MRI scan
87 88 90 91 92 93 94 95 96 97 98 99	 20. Following laboratory abnormalities at screening*: White blood cells (WBC) <3.0 ≥10³/µL Absolute neutrophil count (ANC) <2.0 ≥10³/µL Absolute lymphocyte count <0.5 ≥10³/µL Platelet count <10 ≥10⁴/µL Platelet count <10 ≥10⁴/µL Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the upper limit of normal (ULN). SAkuraStar: inclusion criteria Patients diagnosed as having either: Optic neuritis Acute myelitis Acute myelitis At least two of three supportive criteria:

103		3. NMO-immunoglobulin G (IgG) (anti-AQP4 antibody)
104		seropositive status
105		 NMOSD as defined by either of the following criteria with anti-AQP4
106		antibodies seropositive status at screening (Wingerchuk 2007 ²):
107		i. Idiopathic single or recurrent events of longitudinally extensive myelitis
108		(≥3 vertebral segment spinal cord MRI lesion)
109		ii. Optic neuritis: single, recurrent or simultaneous bilateral
110	2.	Clinical evidence of at least 1 documented relapse (including first attack) in the last
111		12 months prior to screening
112	3.	Expanded Disability Status Scale (EDSS) score from 0 to 6.5 inclusive at screening.
113	4.	Age 18 to 74 years, inclusive at the time of informed consent.
114	5.	Ability and willingness to provide written informed consent and to comply with the
115		requirements of the protocol.
116	SAku	raStar: exclusion criteria
117	Exclu	sion criteria related to NMOSD
118	1.	Clinical relapse onset (including first attack) within 30 days prior to baseline.
119	Prior	therapies
120		Any previous treatment with IL-6 inhibitory therapy (e.g., tocilizumab), alemtuzumab,
121		total body irradiation or bone marrow transplantation at any time.
122	3.	Any previous treatment with anti-CD20, eculizumab, anti-B-lymphocyte stimulator
123		(BLyS) monoclonal antibody (e.g., belimumab), any other treatment for prevention of
124		MS relapse (e.g., interferon, natalizumab, glatiramer acetate, fingolimod,
125		teriflunomide or dimethyl fumarate) within 6 months prior to baseline.
126	4.	Any previous treatment with anti-CD4, cladribine, cyclosphosphamide or
127		mitoxantrone within 2 years prior to baseline.
128	5.	Treatment with any investigational agent within 3 months prior to baseline.
129	Gener	ral safety – see SAkuraSky criteria, plus:
130	See S	AkuraSky criteria, plus:
131	6	History of Stevens-Johnson syndrome.
	0.	·······
132		atory exclusion criteria (at screening)
133	See S	AkuraSky criteria.

135 Protocol-defined relapse criteria


The primary endpoint of both studies was time to first protocol-defined relapse (PDR). PDRs
were new or worsening objective neurological symptoms with at least one of the following:

- Increase of ≥1.0 EDSS points from a baseline EDSS score of >0 (or ≥2.0 EDSS
 points from a baseline EDSS score of 0)
- Increase of ≥2.0 points on ≥1 appropriate symptom-specific functional system scores
 (FSS) for either pyramidal, cerebellar, brainstem, sensory, bowel or bladder, or a
 single eye
- Increase of ≥1.0 points on ≥2 symptom-specific FSS with a baseline of ≥1.0
- Increase of ≥1.0 points on a single-eye symptom-specific FSS with a baseline score
 of ≥1.0
- 146 Symptoms must be attributable to NMOSD, persisting for more than 24 hours, and not
- 147 attributable to confounding clinical factors such as fever, infection, injury, change in mood, or
- adverse reactions to medications. EDSS and FSS were assessed within 7 days of a patient
- reporting their symptoms. PDRs were adjudicated by an independent Clinical EndpointCommittee (CEC).
- 151
- 152

153


154 Supplementary tables and figures

155 eFigure 1: SAkuraSky and SAkuraStar study designs



CEC, Clinical Endpoint Committee; IST, immunosuppressive therapy; OST, overall satralizumab treatment period; LA, last administration; LO, last observation

Treatment administered. *CEC-confirmed protocol-defined relapse or clinical relapse requiring rescue therapy in SAkuraSky; CEC-confirmed protocol-defined relapse in SAkuraStar.



eFigure 2: Kaplan-Meier analysis of time to first severe PDR in the double-blind 156 periods of a) SAkuraSky and b) SAkuraStar 157

162 **References**

Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised
 diagnostic criteria for neuromyelitis optica. *Neurology*. May 23 2006;66(10):1485-9.
 doi:10.1212/01.wnl.0000216139.44259.74

166 2. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The

spectrum of neuromyelitis optica. *The Lancet Neurology*. 2007;6(9):805-815.

168 doi:10.1016/S1474-4422(07)70216-8

169